Accueil
tpex

The Lancet Oncology on X: NEW: phase 2 GORTEC 2014-01 TPExtreme trial: TPEx (cetuximab+docetaxel+cisplatin) vs EXTREME (platinum+fluorouracil+cetuximab) in recurrent or metastatic head and neck squamous-cell carcinoma #headandneckcancer

Par un écrivain mystérieux

Description
The Lancet Oncology on X: NEW: phase 2 GORTEC 2014-01 TPExtreme trial: TPEx (cetuximab+docetaxel+cisplatin) vs EXTREME (platinum+fluorouracil+cetuximab) in recurrent or metastatic head and neck squamous-cell carcinoma #headandneckcancer
Frontiers TTCC-2019-02: real-world evidence of first-line
The Lancet Oncology on X: NEW: phase 2 GORTEC 2014-01 TPExtreme trial: TPEx (cetuximab+docetaxel+cisplatin) vs EXTREME (platinum+fluorouracil+cetuximab) in recurrent or metastatic head and neck squamous-cell carcinoma #headandneckcancer
Frontiers The Evolving Role of Taxanes in Combination With
The Lancet Oncology on X: NEW: phase 2 GORTEC 2014-01 TPExtreme trial: TPEx (cetuximab+docetaxel+cisplatin) vs EXTREME (platinum+fluorouracil+cetuximab) in recurrent or metastatic head and neck squamous-cell carcinoma #headandneckcancer
Frontiers Cetuximab-Containing Combinations in Locally Advanced
The Lancet Oncology on X: NEW: phase 2 GORTEC 2014-01 TPExtreme trial: TPEx (cetuximab+docetaxel+cisplatin) vs EXTREME (platinum+fluorouracil+cetuximab) in recurrent or metastatic head and neck squamous-cell carcinoma #headandneckcancer
Gemcitabine–cisplatin versus MVAC chemotherapy for urothelial
The Lancet Oncology on X: NEW: phase 2 GORTEC 2014-01 TPExtreme trial: TPEx (cetuximab+docetaxel+cisplatin) vs EXTREME (platinum+fluorouracil+cetuximab) in recurrent or metastatic head and neck squamous-cell carcinoma #headandneckcancer
Taking a Closer Look at Recurrent/Metastatic SCCHN - ppt download
The Lancet Oncology on X: NEW: phase 2 GORTEC 2014-01 TPExtreme trial: TPEx (cetuximab+docetaxel+cisplatin) vs EXTREME (platinum+fluorouracil+cetuximab) in recurrent or metastatic head and neck squamous-cell carcinoma #headandneckcancer
Frontiers A Multicenter Phase II Trial of Docetaxel, Cisplatin
The Lancet Oncology on X: NEW: phase 2 GORTEC 2014-01 TPExtreme trial: TPEx (cetuximab+docetaxel+cisplatin) vs EXTREME (platinum+fluorouracil+cetuximab) in recurrent or metastatic head and neck squamous-cell carcinoma #headandneckcancer
Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus
The Lancet Oncology on X: NEW: phase 2 GORTEC 2014-01 TPExtreme trial: TPEx (cetuximab+docetaxel+cisplatin) vs EXTREME (platinum+fluorouracil+cetuximab) in recurrent or metastatic head and neck squamous-cell carcinoma #headandneckcancer
Induction chemotherapy with docetaxel, cisplatin and 5
The Lancet Oncology on X: NEW: phase 2 GORTEC 2014-01 TPExtreme trial: TPEx (cetuximab+docetaxel+cisplatin) vs EXTREME (platinum+fluorouracil+cetuximab) in recurrent or metastatic head and neck squamous-cell carcinoma #headandneckcancer
What Is New in Metastatic Colorectal Cancer?
The Lancet Oncology on X: NEW: phase 2 GORTEC 2014-01 TPExtreme trial: TPEx (cetuximab+docetaxel+cisplatin) vs EXTREME (platinum+fluorouracil+cetuximab) in recurrent or metastatic head and neck squamous-cell carcinoma #headandneckcancer
Radiotherapy plus cetuximab or cisplatin in human papillomavirus
The Lancet Oncology on X: NEW: phase 2 GORTEC 2014-01 TPExtreme trial: TPEx (cetuximab+docetaxel+cisplatin) vs EXTREME (platinum+fluorouracil+cetuximab) in recurrent or metastatic head and neck squamous-cell carcinoma #headandneckcancer
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil
depuis par adulte (le prix varie selon la taille du groupe)